

Amendments to the Claims

Claim 1 (Cancelled)

¹
Claim ~~2~~ (Currently amended): A method of inhibiting an antigen-specific response of a T cell to subsequent presentation of said antigen, comprising administering to said T cell an effective amount of exogenous interleukin-10 and said antigen *in vitro*.

²
Claim ~~3~~ (Previously presented): The method of Claim ~~2~~:

a) wherein said T cell response is mediated by a macrophage, APC, langerhans cell, or dendritic cell;

b) further inhibiting proliferative response of CD4+ host-reactive T cell clones;

or

c) wherein said inhibiting persists for at least about 21 days.

³
Claim ~~4~~ (Original): The method of Claim ~~2~~, wherein said effective amount is sufficient to decrease responder T cell activation.

⁴
Claim ~~5~~ (Previously presented): The method of Claim ~~4~~, further comprising reduced T cell-stimulatory capacity of peripheral blood mononuclear cells, dendritic cells, monocytes, and/or normal B cells.

Claims 6-14 (Cancelled)

⁵
Claim ~~15~~ (Currently amended): A method of suppressing a T cell response to an antigen, comprising administering to said T cell *in vitro* a combination of:

- a) IL-10; and
- b) either said antigen or anti-CD3 antibodies.

⁶
Claim ~~16~~ (Original): The method of Claim ~~15~~⁵, wherein said antigen is alloantigen or self antigen.

⁷
Claim ~~17~~ (Original): The method of Claim ~~16~~⁶, wherein said antigen is restricted by MHC molecules.

Claim 18 (Canceled)

⁸
Claim ~~19~~ (Previously presented) The method of Claim 15, ~~which~~ further comprising suppressing a T cell response to subsequent stimulation to said antigen.

⁹
Claim ~~20~~ (Previously presented): The method of Claim ~~19~~⁸, wherein said response to subsequent stimulation accompanies tissue transplantation.

¹⁰
Claim ~~21~~ (Original): The method of Claim ~~20~~⁹, wherein said tissue is an organ or bone marrow.

¹¹
Claim ~~22~~ (Original): The method of Claim ~~20~~⁹, wherein said T cell is from the recipient of said tissue transplantation.

¹²
Claim ~~23~~ (Currently amended): The method of Claim ~~15~~⁵, wherein said response accompanies tissue transplantation and:

- a) said administering is prior to said tissue transplantation;
- b) said T cell is introduced to the recipient of said tissue transplantation; or
- c) IL-10 is administered to the tissue to be transplanted before said transplantation.

13
Claim ~~24~~ (Original): The method of Claim ~~16~~, wherein said antigen causes an autoimmune disease.

14
Claim ~~25~~ (Currently amended): A method of suppressing a subsequent response of a T cell to an antigen, comprising administering to a T cell in vitro a combination of:

- a) exogenous IL-10; and
- b) either antigen or anti-CD3 antibodies.

15
Claim ~~26~~ (Original): The method of Claim ~~25~~, wherein said IL-10 is administered for at least about 7 days.

16
Claim ~~27~~ (Currently amended): A method of inducing ~~in T cell~~ anergy to an MHC antigen in a T cell, comprising administering to a precursor of said T cell precursor in vitro;

- a) exogenous IL-10 and said antigen; or
- b) exogenous IL-10 and an anti-CD3 antibody.

Claims 28-30 (Cancelled)